Journal of Hematopoietic Cell Transplantation
Online ISSN : 2186-5612
ISSN-L : 2186-5612
Review
Clinical trials of combining the data from the Japan Society for Hematopoietic cell transplantation (JSHCT) and the Japan Adult Leukemia Study Group (JALSG)
—A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission—
Shinichi Kako
Author information
JOURNAL FREE ACCESS

2017 Volume 6 Issue 1 Pages 8-14

Details
Abstract

 The execution of a prospective trial involving the random assignment of adult patients with acute lymphoblastic leukemia (ALL) in first remission who have a human leukocyte antigen (HLA) -matched related donor into 1 of the 2 groups, those undergoing hematopoietic stem cell transplantation (HSCT) or those treated with chemotherapy alone, is difficult in terms of practicality. Therefore, we performed a decision analysis to establish the optimal post-remission treatment in such patients. Transition probabilities after continuing chemotherapy in the first remission period, and after treatment with HSCT in patients with various disease statuses, were established according to the results of Japan Adult Leukemia Study Group (JALSG) prospective studies, and data from the Transplant Registry Unified Management Program (TRUMP) of Japan Society for Hematopoietic cell transplantation (JSHCT), respectively. As a result, the decision to perform HSCT in the first remission period, as opposed to continuing treatment with chemotherapy in this period, is recommended for adult patients with ALL who have an HLA-matched related donor. In addition, we were able to demonstrate efficacy when combining the large amount of clinical data regarding chemotherapy and HSCT. Further improvement in two large nationwide data obtained from results of JALSG studies regarding chemotherapy and from TRUMP of JSHCT regarding HSCT is anticipated, and the direct association between these 2 large data will generate important results with respect to treatment strategies for hematological diseases in Japan.

Content from these authors
© 2017 The Japan Society for Hematopoietic Stem Cell Transplantation
Previous article Next article
feedback
Top